Cerberus Ventures led a $54.4m Series B funding round in Ansa Biotechnologies.

Cerberus Ventures, a private equity firm, led a $54.4m Series B funding round in Ansa Biotechnologies, a biotechnology company, with participation from Blue Water Life Science Advisors, Altitude Life Science Ventures, Fall Line Capital, AIM13, and Black Opal Ventures, and other existing investors. "We believe Ansa’s guaranteed approach fills a huge unmet need, and should become the new standard for DNA synthesis," Chenny Zhang, Cerberus Ventures Director.